Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 7/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608958 | 0.84 | HTR2A (0.48) | HTR2AHTR2CMAPTPDE4APDE4B | |
| SCHEMBL10375756 | 0.82 | KCNA3 (0.44) | KCNA3MAPTALDH1A1SCN2AKMO | |
| SCHEMBL2608966 | 0.81 | HTR2C (0.49) | HTR2AHTR2CDPP4MAPTMEN1 | |
| SCHEMBL18926938 | 0.79 | SMN1; SMN2 (0.47) | HTR2AHTR2CALDH1A1 | |
| SCHEMBL24144837 | 0.79 | HTR2C (0.58) | HTR2AHTR2CMEN1ALDH1A1KMT2A | |
| SCHEMBL28812790 | 0.76 | NTRK1 (0.38) | KCNA3MAPTALDH1A1NTRK1 | |
| SCHEMBL4033420 | 0.76 | HTR2C (0.77) | HTR2AHTR2CMEN1ALDH1A1KMT2A | |
| SCHEMBL2644030 | 0.74 | CPT1A (0.44) | KCNA3MAPTPDE4APDE4BPDE4C | |
| SCHEMBL6050596 | 0.73 | MAT2A (0.44) | ALDH1A1KMONTRK1 | |
| SCHEMBL24143218 | 0.73 | ICMT (0.42) | HTR2AHTR2CKCNA3DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | HTR2A 4221/4885HTR2C 4182/4885KCNA3 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.